HealthStream, Inc. (HSTM) Receives $25.00 Consensus Target Price from Analysts

Acadian Asset Management LLC increased its position in HealthStream by 51.7% during the 3rd quarter. Acadian Asset Management LLC now owns …

HealthStream logoHealthStream, Inc. (NASDAQ:HSTM) has earned a consensus rating of “Hold” from the eight research firms that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.00.

HSTM has been the subject of several analyst reports. Zacks Investment Research upgraded shares of HealthStream from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research report on Wednesday, January 16th. ValuEngine upgraded shares of HealthStream from a “hold” rating to a “buy” rating in a research report on Wednesday, January 2nd. TheStreet cut shares of HealthStream from a “b-” rating to a “c+” rating in a research report on Tuesday, November 20th. Finally, Barrington Research restated a “hold” rating on shares of HealthStream in a research report on Monday, January 14th.

Shares of NASDAQ:HSTM opened at $26.88 on Wednesday. The company has a market capitalization of $845.96 million, a PE ratio of 99.56, a PEG ratio of 3.92 and a beta of 0.69. HealthStream has a 12 month low of $23.06 and a 12 month high of $31.86.

Large investors have recently modified their holdings of the company. BB&T Corp acquired a new position in HealthStream during the 3rd quarter worth approximately $205,000. First Quadrant L P CA acquired a new position in HealthStream during the 3rd quarter worth approximately $634,000. Conestoga Capital Advisors LLC increased its position in HealthStream by 14.2% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,773,237 shares of the technology company’s stock worth $54,988,000 after purchasing an additional 220,863 shares in the last quarter. Acadian Asset Management LLC increased its position in HealthStream by 51.7% during the 3rd quarter. Acadian Asset Management LLC now owns 175,624 shares of the technology company’s stock worth $5,444,000 after purchasing an additional 59,845 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in HealthStream by 5.8% during the 3rd quarter. Wells Fargo & Company MN now owns 42,062 shares of the technology company’s stock worth $1,304,000 after purchasing an additional 2,307 shares in the last quarter. Institutional investors own 69.60% of the company’s stock.

HealthStream Company Profile

HealthStream, Inc provides workforce and provider solutions for healthcare organizations in the United States. It operates through HealthStream Workforce Solutions and HealthStream Provider Solutions segments. The company offers workforce development solutions comprising software-as-a-service (SaaS) and subscription-based products to meet talent management, training, certification, competency assessment, performance appraisal, and development needs, as well as training, implementation, and account management services.

Read More: Mutual Funds

Receive News & Ratings for HealthStream Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HealthStream and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Credit Acceptance Corp. (CACC) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in Credit Acceptance Corp. (NASDAQ:CACC) by 27.3% in the 3rd quarter, according to its most …

Credit Acceptance logoRenaissance Technologies LLC decreased its position in Credit Acceptance Corp. (NASDAQ:CACC) by 27.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 800 shares of the credit services provider’s stock after selling 300 shares during the period. Renaissance Technologies LLC’s holdings in Credit Acceptance were worth $350,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. First Hawaiian Bank acquired a new position in Credit Acceptance in the 3rd quarter valued at about $178,000. Grandfield & Dodd LLC acquired a new position in shares of Credit Acceptance during the 3rd quarter worth approximately $224,000. Virtu Financial LLC acquired a new position in shares of Credit Acceptance during the 3rd quarter worth approximately $224,000. C M Bidwell & Associates Ltd. bought a new stake in shares of Credit Acceptance during the 3rd quarter worth approximately $245,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Credit Acceptance during the 3rd quarter worth approximately $251,000. 61.90% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages recently commented on CACC. Zacks Investment Research raised shares of Credit Acceptance from a “hold” rating to a “buy” rating and set a $468.00 price objective for the company in a research note on Monday, February 4th. BMO Capital Markets increased their price objective on shares of Credit Acceptance to $390.00 and gave the stock a “market perform” rating in a research report on Monday, February 4th. Oppenheimer reissued a “market perform” rating on shares of Credit Acceptance in a research report on Thursday, January 31st. They noted that the move was a valuation call. BTIG Research assumed coverage on shares of Credit Acceptance in a research report on Wednesday, January 23rd. They set a “sell” rating and a $340.00 price target on the stock. Finally, BidaskClub raised shares of Credit Acceptance from a “hold” rating to a “buy” rating in a research report on Saturday, January 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. Credit Acceptance currently has a consensus rating of “Hold” and an average price target of $381.88.

Shares of Credit Acceptance stock opened at $441.29 on Friday. Credit Acceptance Corp. has a 12-month low of $299.00 and a 12-month high of $467.26. The company has a current ratio of 17.07, a quick ratio of 36.75 and a debt-to-equity ratio of 1.83. The firm has a market cap of $8.20 billion, a price-to-earnings ratio of 15.54, a P/E/G ratio of 1.06 and a beta of 0.62.

Credit Acceptance (NASDAQ:CACC) last announced its quarterly earnings data on Wednesday, January 30th. The credit services provider reported $7.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.45 by $0.40. The business had revenue of $342.80 million during the quarter, compared to analyst estimates of $338.73 million. Credit Acceptance had a net margin of 44.64% and a return on equity of 29.89%. The company’s revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted $5.16 EPS. On average, analysts forecast that Credit Acceptance Corp. will post 32.73 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Credit Acceptance Corp. (CACC) Shares Sold by Renaissance Technologies LLC” was first published by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/02/16/renaissance-technologies-llc-trims-position-in-credit-acceptance-corp-cacc.html.

About Credit Acceptance

Credit Acceptance Corporation provides financing programs, and related products and services to independent and franchised automobile dealers in the United States. The company advances money to dealers in exchange for the right to service the underlying consumer loans; and buys the consumer loans from the dealers and keeps various amounts collected from the consumers.

Read More: What is the 52-week high/low?

Institutional Ownership by Quarter for Credit Acceptance (NASDAQ:CACC)

Receive News & Ratings for Credit Acceptance Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Credit Acceptance and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Increases Stake in AcelRx Pharmaceuticals Inc (ACRX)

BlackRock Inc. lifted its stake in shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 16.8% in the 3rd quarter, according to its most recent Form …

AcelRx Pharmaceuticals logoBlackRock Inc. lifted its stake in shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 16.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 786,034 shares of the specialty pharmaceutical company’s stock after purchasing an additional 112,919 shares during the quarter. BlackRock Inc. owned about 1.27% of AcelRx Pharmaceuticals worth $3,026,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 273,644 shares during the period. Renaissance Technologies LLC bought a new position in AcelRx Pharmaceuticals in the 2nd quarter worth approximately $1,676,000. Creative Planning boosted its holdings in AcelRx Pharmaceuticals by 256.1% in the 3rd quarter. Creative Planning now owns 45,222 shares of the specialty pharmaceutical company’s stock worth $174,000 after buying an additional 32,522 shares during the period. Cedar Wealth Management LLC boosted its holdings in AcelRx Pharmaceuticals by 182.5% in the 3rd quarter. Cedar Wealth Management LLC now owns 33,895 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 21,895 shares during the period. Finally, Fosun International Ltd bought a new position in AcelRx Pharmaceuticals in the 3rd quarter worth approximately $1,940,000. Institutional investors and hedge funds own 10.79% of the company’s stock.

Shares of NASDAQ:ACRX opened at $2.90 on Friday. AcelRx Pharmaceuticals Inc has a one year low of $1.65 and a one year high of $5.05. The firm has a market capitalization of $179.53 million, a price-to-earnings ratio of -2.64 and a beta of 1.99.

In other news, CEO Vincent J. Angotti purchased 10,000 shares of the business’s stock in a transaction on Wednesday, December 12th. The stock was purchased at an average cost of $2.99 per share, with a total value of $29,900.00. Following the acquisition, the chief executive officer now directly owns 51,040 shares in the company, valued at $152,609.60. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Pamela P. Palmer purchased 16,000 shares of the business’s stock in a transaction on Monday, November 19th. The stock was purchased at an average cost of $3.07 per share, with a total value of $49,120.00. Following the completion of the acquisition, the insider now owns 472,134 shares in the company, valued at $1,449,451.38. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 34,610 shares of company stock valued at $102,956. Insiders own 25.50% of the company’s stock.

Several research analysts recently commented on the stock. Credit Suisse Group assumed coverage on shares of AcelRx Pharmaceuticals in a report on Friday. They issued an “outperform” rating and a $7.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of AcelRx Pharmaceuticals in a report on Wednesday, December 12th. Cantor Fitzgerald set a $8.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 25th. Royal Bank of Canada set a $7.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 22nd. Finally, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, November 19th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $7.78.

WARNING: “BlackRock Inc. Increases Stake in AcelRx Pharmaceuticals Inc (ACRX)” was posted by Fairfield Current and is the property of of Fairfield Current. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/02/16/blackrock-inc-has-3-03-million-position-in-acelrx-pharmaceuticals-inc-acrx.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

See Also: What is the Stochastic Momentum Index (SMI)?

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

2U Target of Unusually High Options Trading (TWOU)

2U Inc (NASDAQ:TWOU) saw unusually large options trading activity on Thursday. Traders bought 1,373 call options on the stock. This is an increase …

2U logo2U Inc (NASDAQ:TWOU) saw unusually large options trading activity on Thursday. Traders bought 1,373 call options on the stock. This is an increase of approximately 2,012% compared to the average volume of 65 call options.

NASDAQ TWOU opened at $68.64 on Friday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.04. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -127.11 and a beta of 0.66. 2U has a one year low of $44.50 and a one year high of $98.58.

Several research firms recently commented on TWOU. BidaskClub raised shares of 2U from a “buy” rating to a “strong-buy” rating in a research note on Friday. DA Davidson set a $80.00 price target on shares of 2U and gave the stock a “buy” rating in a research note on Tuesday, November 6th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $72.00 price target on shares of 2U in a research note on Tuesday. Piper Jaffray Companies reduced their price target on shares of 2U to $76.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 6th. Finally, Credit Suisse Group reduced their price target on shares of 2U from $100.00 to $80.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 6th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $81.45.

In related news, Director Gregory K. Peters purchased 9,761 shares of 2U stock in a transaction that occurred on Monday, November 19th. The shares were bought at an average price of $51.22 per share, with a total value of $499,958.42. Following the purchase, the director now directly owns 11,156 shares of the company’s stock, valued at approximately $571,410.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. purchased a new position in 2U during the 3rd quarter valued at about $263,000. Vanguard Group Inc increased its position in 2U by 4.0% during the 3rd quarter. Vanguard Group Inc now owns 4,811,529 shares of the software maker’s stock valued at $361,779,000 after purchasing an additional 184,555 shares during the period. Bank of New York Mellon Corp increased its position in 2U by 45.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 897,043 shares of the software maker’s stock valued at $67,448,000 after purchasing an additional 281,011 shares during the period. BlackRock Inc. increased its position in 2U by 4.1% during the 3rd quarter. BlackRock Inc. now owns 2,481,041 shares of the software maker’s stock valued at $186,550,000 after purchasing an additional 98,822 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of 2U by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,811,529 shares of the software maker’s stock worth $361,779,000 after buying an additional 184,555 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “2U Target of Unusually High Options Trading (TWOU)” was originally posted by PressOracle and is the property of of PressOracle. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://pressoracle.com/news/2019/02/16/2u-target-of-unusually-high-options-trading-twou.html.

2U Company Profile

2U, Inc operates as an education technology company in the United States, Hong Kong, South Africa, and the United Kingdom. The company operates through two segments, Graduate Program Segment and Short Course Segment. It offers front-end technology and services, including online learning platform, student and faculty and immersion support, accessibility, admissions application advising, in-program student field placements, and faculty recruiting.

Further Reading: Trading Strategy Examples and Plans

Receive News & Ratings for 2U Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for 2U and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Trading Focus: Zooming in on iRobot Corporation (NASDAQ:IRBT)

Tracking recent action on shares of iRobot Corporation (NASDAQ:IRBT) we have noted that the stock price has been spotted trading around $115.28.

Tracking recent action on shares of iRobot Corporation (NASDAQ:IRBT) we have noted that the stock price has been spotted trading around $115.28. Investors may be closely following price activity on the stock over the next few trading periods. Investors will be trying to gauge which way market momentum will trend as we move into the close of the calendar year.

As the next earnings season comes into focus, investors will be keeping watch on the performance of companies that they own. A company that continually exceeds earnings projections is most likely on the right track. On the other end of the spectrum, a company that frequently misses earnings projections might provide some insight to the fact that something isn’t right. Although it is important to keep track of earnings estimates and results, it shouldn’t be the only thing that the investor is looking at regarding the stock. Just because a company misses or beats expectations for one quarter may not mean anything super special. Tracking performance over a longer period of time can help paint the bigger picture of what is going on with the company. Sharp investors often have the ability to look deeper into the numbers to see the actual causes of an earnings hit or miss. Of course estimates are just that, estimates, and some analysts may be more accurate than others.

Sell-side analysts often undertake stock analysis to give their opinions of whether they believe that shares should be bought, sold, or held. Using ratings provided by analysts polled by Zacks Research, we note that the current average broker rating on shares of iRobot Corporation (NASDAQ:IRBT) is currently 2.38. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock. After a recent check, we can see that 3 sell-side analysts have rated the stock a Strong Buy or Buy, based analysts polled by Zacks Research. Professional investors often incorporate various strategies when approaching the stock market. Capitalizing on market dips can be highly profitable when thoroughly researched and executed. Closely monitoring earnings, news, and analyst views may play an important role in equity study.

Shares of iRobot Corporation (NASDAQ:IRBT) currently have an average target price of 92.2. This is the consensus number using estimates given by polled analysts. Professional Wall Street analysts that track the stock are constantly monitoring the company to assess where they believe shares will be moving in the future. Price target projections can be calculated using various methods. Many investors will follow stock target prices, especially when analysts make revisions.

The average investor might not have the time to monitor every single movement of a certain stock. Tracking the historical performance may help provide some valuable insight on where the stock may be trending in the future. Looking back over the last 4 weeks, shares of iRobot Corporation (NASDAQ:IRBT) have moved 30.99%. Over the last 5 days, the stock has seen a change of 17.58%. Looking at the last 12 week period, we note that the stock has moved 27.76%. Since the beginning of the calendar year, we note that shares have changed 37.66%. Investors will often track the current stock price relative to its 52-week high and low levels. The 52-week high is currently 117.71, and the 52-week low is resting at 57.06. When shares are trading near the 52-week high or 52-week low, investors may be on the lookout for a breakout.

Investors are constantly looking to find winning stocks that have been largely overlooked. With markets still riding high, this may not be the easiest thing in the world right now. Finding those perfect stocks before they become household names may take a lot of research and homework. Many investors will apply various strategies for picking stocks. If there was one that worked for everybody, it would make things super easy. Of course, this is not the case. Obviously, there are no guarantees in the stock market. Some investors may only focus on the fundamentals of a company and completely ignore the technicals. Others may choose to only watch technicals and never take a look at the underlying company information. Combining both areas of research may help give a better feel of what is going on with the stock in the long term and the short term. Individual investors who manage their own portfolios may need to put in a lot more time than those who don’t. Successful investors often have an uncanny way of filtering out the noise and keeping their focus on the right information.

Related Posts:

  • No Related Posts